Physician profile
James Koch
NPI 1164625794
$10,743.23
in general payments reported to CMS, 2019-2025
69 companies · $1,485 in 2025
The $1,485 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,429 · 2020: $1,187 · 2021: $1,802 · 2022: $1,539 · 2023: $1,456 · 2024: $1,844 · 2025: $1,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,686 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,685.53 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,354.00 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $1,021.99 | 2019-2025 | |
| Pfizer INC. | $508.46 | 2023-2025 | |
| Emd Serono, INC. | $507.61 | 2019-2025 | Mavenclad |
| Argenx US, INC. | $474.67 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Genzyme Corporation | $442.35 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $368.08 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lilly USA, LLC | $367.29 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Supernus Pharmaceuticals, INC. | $339.09 | 2019-2021 | |
| Ucb, INC. | $325.76 | 2019-2025 | Zilbrysq, Nayzilam |
| Allergan, INC. | $266.92 | 2019-2021 | |
| Kyowa Kirin, INC. | $248.77 | 2020-2024 | Nourianz |
| Biohaven Pharmaceuticals, INC. | $231.24 | 2021 | |
| Sk Life Science, INC. | $228.28 | 2020-2024 | |
| Amgen INC. | $213.14 | 2019-2024 | Aimovig, Uplizna |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Koch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.